Integrative Genomic Analysis of PPP3R1 in Alzheimer's Disease: a Potential Biomarker for Predictive, Preventive, and Personalized Medical Approach

Overview

Journal EPMA J

Date 2021 Dec 27

PMID 34956428

Citations 4

Authors

Zhike Zhou

Jun Bai

Shanshan Zhong

Rongwei Zhang

Kexin Kang

Xiaoqian Zhang

Ying Xu

Chuansheng Zhao

Mei Zhao

Affiliations

Soon will be listed here.

Abstract

Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-021-00261-2.

Citing Articles

Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.

Xu Y, Wang Z, Jia T, Liang S PLoS One. 2025; 20(1):e0316481.

PMID: 39823480 PMC: 11741580. DOI: 10.1371/journal.pone.0316481.

Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer's Disease: Beneficial or Detrimental?.

Lin T, Huang C, Lin K, Hsieh Y, Chen S, Lin Y Antioxidants (Basel). 2024; 13(11).

PMID: 39594520 PMC: 11591038. DOI: 10.3390/antiox13111378.

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer's disease.

Cruchaga C, Ali M, Shen Y, Do A, Wang L, Western D Res Sq. 2024; .

PMID: 38410465 PMC: 10896368. DOI: 10.21203/rs.3.rs-3631708/v1.

Identification of immune microenvironment subtypes and signature genes for Alzheimer's disease diagnosis and risk prediction based on explainable machine learning.

Lai Y, Lin P, Lin F, Chen M, Lin C, Lin X Front Immunol. 2022; 13:1046410.

PMID: 36569892 PMC: 9773397. DOI: 10.3389/fimmu.2022.1046410.

Downregulation of PIK3CB Involved in Alzheimer's Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway.

Zhou Z, Bai J, Zhong S, Zhang R, Kang K, Zhang X Oxid Med Cell Longev. 2022; 2022:1260161.

PMID: 35096262 PMC: 8794666. DOI: 10.1155/2022/1260161.

References

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Golubnitschaja O, Costigliola V . General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012; 3(1):14. PMC: 3485619. DOI: 10.1186/1878-5085-3-14. View

Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba M . SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. Neuron. 2019; 103(2):217-234.e4. PMC: 6764089. DOI: 10.1016/j.neuron.2019.05.002. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Wang Y, LeCao K . Managing batch effects in microbiome data. Brief Bioinform. 2019; 21(6):1954-1970. DOI: 10.1093/bib/bbz105. View

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

Alberdi E, Sanchez-gomez M, Cavaliere F, Perez-Samartin A, Zugaza J, Trullas R . Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010; 47(3):264-72. DOI: 10.1016/j.ceca.2009.12.010. View

Karch C, Jeng A, Goate A . Calcium phosphatase calcineurin influences tau metabolism. Neurobiol Aging. 2012; 34(2):374-86. PMC: 3879081. DOI: 10.1016/j.neurobiolaging.2012.05.003. View

Procter A, Palmer A, Francis P, Lowe S, Neary D, Murphy E . Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem. 1988; 50(3):790-802. DOI: 10.1111/j.1471-4159.1988.tb02983.x. View

10.

Rynearson K, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P . Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention. J Exp Med. 2021; 218(4). PMC: 7931646. DOI: 10.1084/jem.20202560. View

11.

Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar M, Okamoto S . Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013; 110(27):E2518-27. PMC: 3704025. DOI: 10.1073/pnas.1306832110. View

12.

Hardingham G . Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer's Disease?. Cell Metab. 2020; 31(3):439-440. DOI: 10.1016/j.cmet.2020.02.009. View

13.

Goodell D, Zaegel V, Coultrap S, Hell J, Bayer K . DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017; 19(11):2231-2243. PMC: 5549467. DOI: 10.1016/j.celrep.2017.05.068. View

14.

Mookherjee P, Green P, Watson G, Marques M, Tanaka K, Meeker K . GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J Alzheimers Dis. 2011; 26(3):447-55. PMC: 3256092. DOI: 10.3233/JAD-2011-110503. View

15.

Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate A . Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. Alzheimers Dement. 2013; 10(3):366-71. PMC: 3809344. DOI: 10.1016/j.jalz.2013.02.010. View

16.

Li S, Jin M, Koeglsperger T, Shepardson N, Shankar G, Selkoe D . Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011; 31(18):6627-38. PMC: 3100898. DOI: 10.1523/JNEUROSCI.0203-11.2011. View

17.

Chan K, Wu J, Liu L, Theodoratou E, Car J, Middleton L . Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet. 2013; 381(9882):2016-23. DOI: 10.1016/S0140-6736(13)60221-4. View

18.

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M . Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016; 7:23. PMC: 5078893. DOI: 10.1186/s13167-016-0072-4. View

19.

Cruchaga C, Kauwe J, Mayo K, Spiegel N, Bertelsen S, Nowotny P . SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010; 6(9):e1001101. PMC: 2940763. DOI: 10.1371/journal.pgen.1001101. View

20.

Gozes I . Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. EPMA J. 2017; 8(3):255-259. PMC: 5607150. DOI: 10.1007/s13167-017-0110-x. View